Crysta raises Rs 10 crores pre-Series A funding round
The investment will enable in scaling up Crysta and help improve Redcliffe Life Sciences’ market reach and technological capabilities
Crysta recently raised Rs 10 crores in a pre-Series A funding round led by the family office of Ruchirans and Anuraag Jaipuria. The investors also include several family fund including Mumbai-based Green Shots Capital and Alfa Ventures, Delhi-based Real Time Ventures and NGB Dx, Dubai-based Petrotech, Steel City Securities and angel investors Lalit Wadhwa, Dr Kriti Maroli among others.
Speaking about the investment, Dheeraj Jain, Founder, Redcliffe Life Sciences, said, “The pre-Series A funding will help us in building an end-to-end reproductive health platform covering all relevant aspects of pregnancy and fertility care. The potential is huge in this segment, and the current round will allow us to scale up Crysta and our other capabilities across major cities. We are also preparing for the $10 million Series A round for a much larger expansion in the mother and child segment. Our scientific team works with all major hospitals for long-term collaboration, apart from research institutes to ensure that we have the best technology in place.”
“Crysta is an amazing disruption in the reproductive health segment. Right from the thought of conceiving, simple hormonal and fertility tests to pre-implantation using NGS and assisted pregnancy all the way to newborn screening, it’s a complete package for couples across all income segments. We believe in the team’s capabilities in using this funding to scale up their technology platform,” said Ruchirans Jaipuria, MD, Jaipuria Beverages.
Ashish Dubey, Co- Founder, Redcliffe Life Sciences, opined, “Our ability to turnaround the results fastest in the market, apart from our in-house sequencing platform and quality test menu make for a compelling case for clinicians to work with us. Unlike the traditional path labs, we focus on high-quality high value segment using molecular sequencing towards precision medicine. This funding also expands other genomics test offering of Redcliffe Life Sciences most importantly exomes sequencing where we have large customer base.”